Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer.Cancer Cell. 2022 01 10; 40(1):3-5.CC
Anti-COVID-19 immunity dynamics were assessed in patients with cancer in a prospective clinical trial. Waning of immunity was detected 4-6 months post-vaccination with significant increases in anti-spike IgG titers after booster dosing, and 56% of seronegative patients seroconverted post-booster vaccination. Prior anti-CD20/BTK inhibitor therapy was associated with reduced vaccine efficacy.